TAK - Takeda Pharmaceutical Company Limited

NYSE - NYSE Delayed price. Currency in USD
18.93
-0.24 (-1.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close19.17
Open19.00
Bid0.00 x 1800
Ask0.00 x 3000
Day's range18.90 - 19.00
52-week range12.43 - 20.93
Volume757,056
Avg. volume1,640,230
Market cap58.561B
Beta (5Y monthly)1.12
PE ratio (TTM)23.33
EPS (TTM)0.81
Earnings dateN/A
Forward dividend & yield0.83 (4.38%)
Ex-dividend date27 Sep 2019
1y target est20.90
  • Business Wire

    U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.

  • TAKU GOLD CORP (TAK) Q4 2019 Earnings Call Transcript
    Motley Fool

    TAKU GOLD CORP (TAK) Q4 2019 Earnings Call Transcript

    TAK earnings call for the period ending March 31, 2020.

  • Seattle Genetics' Adcetris Label Expands in EU for Lymphoma
    Zacks

    Seattle Genetics' Adcetris Label Expands in EU for Lymphoma

    Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

  • Business Wire

    Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline

    Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) ("Takeda") today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29-31 and the 25th Virtual Congress of the European Hematology Association (EHA), June 11-14.

  • Business Wire

    European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) to include treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL), in combination with CHP (cyclophosphamide, doxorubicin, prednisone). Systemic anaplastic large cell lymphoma is a subtype of peripheral T-cell lymphoma (PTCL). The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on March 27, 2020.

  • Pandemic sends Japan April machine tool orders to lowest levels since 2010
    Reuters

    Pandemic sends Japan April machine tool orders to lowest levels since 2010

    Japan's machine tool orders in April fell to their lowest level in more than a decade, preliminary data showed on Thursday, in a sign the coronavirus pandemic is taking an deeper toll on the economy. Machine tool orders in April slumped 48.3% compared with a year earlier, a preliminary estimate from the Japan Machine Tool Builders' Association (JMTBA) showed. "Of course, there was a big decline, and it confirmed that companies are foregoing capital expenditure," said Atsushi Takeda, chief economist at Itochu Economic Research Institute.

  • Takeda says coronavirus treatment trial using recovered patients' blood could start in July
    Reuters

    Takeda says coronavirus treatment trial using recovered patients' blood could start in July

    The clinical trial would include hundreds of patients and take several months to complete. If successful, Japan's Takeda could file for approval by U.S. authorities this year, said Julie Kim, president of the plasma-derived therapies unit of Takeda. "When the product will be available beyond the clinical study is still a bit unclear," Kim said on an investor call.

  • Takeda Pharma logs surprise profit, updates on COVID-19 therapy
    Reuters

    Takeda Pharma logs surprise profit, updates on COVID-19 therapy

    Takeda Pharmaceutical Co booked a surprise operating profit and forecast that income would triple this business year as hefty acquisition costs related to last year's $59 billion Shire takeover recede. Takeda also said it could start clinical trials in July for its plasma-derived therapy for COVID-19, initially called TAK-888, according to plasma division President Julie Kim. Japan's largest drugmaker estimated 355 billion yen ($3.3 billion) in operating profit for the year to March.

  • Business Wire

    Takeda Accelerates Transformation: Solid FY2019 Results, Confidence in FY2020 Growth Momentum

    Takeda Pharmaceutical Company Limited (TOKYO: 4502) (NYSE: TAK) ("Takeda") today announced financial results for the year ended March 31, 2020 (FY2019). As a top 10 global R&D-driven biopharmaceutical company, Takeda is demonstrating its innovation and values in its response to COVID-19 and in positioning itself for long-term success.

  • Codexis(CDXS) Q1 2020 Earnings Call Transcript
    Motley Fool

    Codexis(CDXS) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codexis call to discuss first-quarter 2020 financial results and recent business progress.

  • Business Wire

    European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

    Approval makes Entyvio the only maintenance therapy approved across Europe with both IV and SC formulation options for adult patients with UC or CD

  • Japan's March jobless rate rises to one-year high as coronavirus hits economy
    Reuters

    Japan's March jobless rate rises to one-year high as coronavirus hits economy

    Japan's March jobless rate rose to its highest in a year, while job availability slipped to a more than three-year low, official data showed on Tuesday, as the coronavirus outbreak and containment measures caused the nation's job market to ease. While Japan's comparatively low jobless rate is the envy of many nations, rises in the politically sensitive figure could lead to calls for Prime Minister Shinzo Abe's government to do more to stimulate the economy. The seasonally adjusted unemployment rate rose to 2.5%, its highest level since March last year, internal affairs ministry data showed, and matching economists' 2.5% median forecast.

  • Business Wire

    Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug mobocertinib (TAK-788) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. There are currently no approved therapies designed to treat this specific form of NSCLC. Mobocertinib is a small-molecule tyrosine kinase inhibitor (TKI) designed to selectively target EGFR and human EGFR 2 (HER2) exon 20 insertion mutations.

  • Business Wire

    Takeda Continues Divestiture Strategy with Sale of Select OTC and Non-Core Assets in Europe to Orifarm for Up to Approximately $670M USD

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to divest a portfolio of select non-core over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland to Orifarm Group ("Orifarm"), a fast-growing Danish pharmaceutical company, for up to approximately $670 million USD subject to customary legal and regulatory closing conditions.

  • Johnson & Johnson abandons deal for Takeda's TachoSil surgical patch
    Reuters

    Johnson & Johnson abandons deal for Takeda's TachoSil surgical patch

    Johnson & Johnson said on Friday it abandoned plans to buy Takeda Pharmaceutical’s surgical patch product TachoSil, citing regulatory issues. Takeda, Japan’s biggest drugmaker, announced the sale of TachoSil, a surgical patch to control bleeding, to Johnson & Johnson's subsidiary Ethicon for $400 million last May. "Ethicon and Takeda have mutually decided to terminate the TachoSil transaction, agreeing that it was the right decision given the regulators’ concerns," a representative for Johnson & Johnson said in a statement.

  • Business Wire

    CORRECTING and REPLACING Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

    Please replace the release with the following corrected version due to multiple revisions to the Octapharma boilerplate and inclusion of additional multimedia.

  • Business Wire

    European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ALUNBRIG (brigatinib) to include use as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on February 27, 2020.

  • Business Wire

    Takeda Adopts Executive Compensation Recoupment Policy

    Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") today announced that its Board of Directors approved an executive compensation recoupment policy ("clawback policy"). The adoption of the clawback policy is part of Takeda’s ongoing efforts to further strengthen its commitment to best-in-class corporate governance and is consistent with Takeda’s industry peers.

  • Business Wire

    Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for the extension of the marketing authorization of ADCETRIS® (brentuximab vedotin) and recommended its approval in combination with CHP (cyclophosphamide, doxorubicin, prednisone) as a treatment for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). The positive CHMP opinion is based on the results of the Phase 3 ECHELON-2 study evaluating ADCETRIS in combination with CHP to a standard care, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), in previously untreated patients with CD30+ peripheral T-cell lymphoma (PTCL), including the subtype sALCL. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, which is expressed on the surface of several types of PTCL, including sALCL.

  • EU says Johnson & Johnson's deal for Takeda patch may harm competition
    Reuters

    EU says Johnson & Johnson's deal for Takeda patch may harm competition

    EU antitrust regulators have opened a full investigation into Johnson & Johnson's acquisition of Takeda Pharmaceutical's surgical patch product TachoSil, concerned that the deal could lead to reduced choice and higher prices for customers. Takeda, Japan's biggest drugmaker, announced the sale of TachoSil, a surgical patch for bleeding control, to U.S. giant Johnson & Johnson's subsidiary Ethicon for $400 million last May. The European Commission said a preliminary investigation found cause for concern because TachoSil is the market leader in Europe.

  • Business Wire

    The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that The Lancet published two papers related to Takeda’s dengue vaccine candidate (TAK-003), reporting on results from the 18-month analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial and results from the final 48-month analysis of the Phase 2 DEN-204 trial.1,2 The analyses are consistent with previously reported safety, immunogenicity and efficacy data for TAK-003.3,4,5,6

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more